Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monoamine oxidase A short hairpin RNA (shMAOA) is an RNA interference (RNAi) agent designed to specifically silence the expression of the *MAOA* gene. Monoamine oxidase A is a mitochondrial enzyme that catalyzes the oxidative deamination of biogenic amines and has been increasingly recognized for its role in cancer biology beyond its traditional function in the central nervous system. In various malignancies, including bladder and prostate cancer, MAOA expression is associated with tumor progression, epithelial-mesenchymal transition (EMT), and metabolic reprogramming, particularly in fatty acid metabolism. The shRNA molecule is typically delivered via viral vectors (such as lentivirus) or specialized nanoparticle systems. Once inside the cell, it is processed by the Dicer enzyme into small interfering RNAs (siRNAs) that direct the RNA-induced silencing complex (RISC) to degrade MAOA mRNA, thereby reducing protein levels and inhibiting downstream oncogenic signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monoamine oxidase A short hairpin RNA.